Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

LTBR vs ASTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ASTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

ASTH Overall Winner 6-Pillar Tally: LTBR 0 – 6 ASTH Matrix Metrics: LTBR 0 – 10 ASTH

As of Nov 16, 2026, Astrana Health Inc. (ASTH) is the stronger overall head-to-head candidate over Lightbridge Corp. (LTBR) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LTBR carries a Unified Composite Score of 40.4/100 (SELL) at $3.84 (N/M Forward P/E, 0.0% operating margin), whereas ASTH carries 53.2/100 (HOLD) at $32.94 (9.1x Forward P/E, 2.6% operating margin).

  • Technical & Structure Timing Caution: LTBR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9); meanwhile ASTH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LTBR vs ASTH
LTBR NASDAQ
Lightbridge Corp.
Services-Management Consulting Services
$3.84
-6.34% 1D
Market Cap $164.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 3.45β · 98% Vol
Unified Composite Score
40.4 / 100 SELL
Tech 33.0 Fund 50.0 Flow 56.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.7%), weak momentum, RSI 33
RSI-14: 32.9 · SMA20: $4.76 · SMA50: $5.76
ASTH NASDAQ Head-to-Head Winner
Astrana Health Inc. Common Stock
Services-Management Consulting Services
$32.94
+3.58% 1D
Market Cap $1.6B
TTM Revenue $3.91B
Forward P/E 9.1x
Beta / 30D Vol 0.40β · 60% Vol
Unified Composite Score
53.2 / 100 HOLD
Tech 59.0 Fund 56.0 Flow 59.0 Mom 56.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.6%), weak momentum, RSI 38
RSI-14: 37.8 · SMA20: $35.86 · SMA50: $36.29

6-Pillar Scorecard Institutional Category Breakdown (LTBR 0 – 6 ASTH)

Columns: Metric · LTBR · ASTH
1. Valuation Multiples ASTH
Forward P/E N/M 9.1x
Trailing P/E N/M 30.6x
PEG Ratio N/M N/M
EV / Revenue N/M 0.6x
2. Growth & Scale ASTH
Revenue Growth (YoY) +0.0% +7.1%
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A $3.91B
Market Cap $164.7M $1.6B
3. Profitability & Quality ASTH
Gross Margin N/A 11.0%
Operating Margin 0.0% 2.6%
Net Profit Margin 0.0% 1.4%
Return on Equity (ROE) -14.1% 9.8%
4. Balance Sheet & Cash Flow ASTH
Cash Generation (TTM) -$19M $99M
Cash Flow Margin N/A 2.5%
Net Cash / Leverage $6.61 Book/Sh · -14.1% ROE $581M Net Debt (1.14x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ASTH
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 79.6% (32nd %ile) 56.4% (11th %ile)
Put/Call OI Skew 5.63x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ASTH
OpEx & R&D Intensity N/A 8.4% of Rev ($329M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Electrical Equipment & Parts Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LTBR (0) vs ASTH (10)
Institutional Metric LTBR ASTH Criterion Row Edge
Market Capitalization
Scale
$164.7M $1.6B Larger Scale ASTH
Trailing P/E Ratio
Valuation
N/M 30.6x Lower Multiple ASTH
Forward P/E Ratio
Valuation
N/M 9.1x Lower Multiple ASTH
Revenue Growth (YoY)
Growth
+0.0% +7.1% Higher Growth ASTH
Operating Margin (TTM)
Profitability
0.0% 2.6% Higher Margin ASTH
Net Profit Margin
Profitability
0.0% 1.4% Higher Margin ASTH
Return on Equity (ROE)
Capital Efficiency
-14.1% 9.8% Higher ROE ASTH
52-Week Range Position
Momentum
0% ($4–$20) 44% ($18–$52) Stronger Trend ASTH
Beta / 30D Volatility
Risk Regime
3.45β · 98% Vol 0.40β · 60% Vol Lower Realized Risk ASTH
Unified Institutional Score
Composite Signal
40.4 / 100 (SELL) 53.2 / 100 (HOLD) Higher Composite ASTH
Trailing 12M Revenue (USD)
Operating Scale
N/A $3.91B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 11.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$19M ($6.61 Book/Sh · -14.1% ROE) $99M ($581M Net Debt (1.14x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ASTH +15.79 pp
LTBR: -26.3% · ASTH: -10.51%
3M Horizon ASTH +36.0 pp
LTBR: -51.88% · ASTH: -15.88%
6M Horizon ASTH +49.11 pp
LTBR: -64.61% · ASTH: -15.5%
1Y Horizon ASTH +128.96 pp
LTBR: -78.62% · ASTH: +50.34%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LTBR Revenue ASTH Revenue LTBR Op. Margin ASTH Op. Margin Margin Leader
FY2018 N/A $520M N/A 17.0% ASTH
FY2019 N/A $560M N/A 5.8% ASTH
FY2020 N/A $690M N/A 11.7% ASTH
FY2021 N/A $770M N/A 12.7% ASTH
FY2022 N/A $1.14B N/A 9.1% ASTH
FY2023 N/A $1.39B N/A 6.1% ASTH
FY2024 N/A $2.03B N/A 4.4% ASTH
FY2025 N/A $3.18B N/A 2.5% ASTH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LTBR BREAKDOWN
134d in phase · OBV DISTRIBUTION
Current IV 79.6%
IV Percentile 32nd %ile
Put/Call OI Skew 5.63x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact LTBR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ASTH BREAKDOWN
96d in phase · OBV DISTRIBUTION
Current IV 56.4%
IV Percentile 11th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ASTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LTBR Moat Profile Cyclical / Execution-Driven Positioning
Electrical Equipment & Parts Operator
Competes within the Electrical Equipment & Parts value chain with $164.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ASTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $1.6B market capitalization and 2.6% operating margin.
OpEx & R&D Reinvestment 8.4% of Rev ($329M)
90D Engineering Disclosures 0 Published

Investor FAQ LTBR vs ASTH Key Questions & Quantitative Answers

As of Nov 16, 2026, Astrana Health Inc. (ASTH) is the stronger overall head-to-head candidate over Lightbridge Corp. (LTBR) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LTBR carries a Unified Composite Score of 40.4/100 (SELL) at $3.84 (N/M Forward P/E, 0.0% operating margin), whereas ASTH carries 53.2/100 (HOLD) at $32.94 (9.1x Forward P/E, 2.6% operating margin). Technical & Structure Timing Caution: LTBR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.9); meanwhile ASTH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ASTH leads the Growth & Scale pillar: LTBR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ASTH at +7.1% YoY revenue growth and N/A YoY earnings growth on $3.91B TTM revenue (11.0% gross margin, 2.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LTBR cumulative revenue shifted N/A while ASTH shifted +511.5%. In operating R&D and SG&A reinvestment, LTBR deploys N/A (0 90-day corporate R&D disclosures) versus 8.4% of Rev ($329M) (0 disclosures) for ASTH.

ASTH screens cheaper on headline valuation multiples. LTBR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ASTH trades at 9.1x Forward P/E, 30.6x Trailing P/E, N/M PEG, and 0.6x EV/Revenue (2.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LTBR (-14.1% ROE) versus ASTH (9.8% ROE) capital efficiency.

In options market volatility and institutional positioning, LTBR carries 79.6% implied volatility (32nd %ile, Balanced (25th–60th %ile)), a 5.63x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.45β · 98% Vol realized risk). By comparison, ASTH carries 56.4% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.40β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.